Navigation Links
Antibody-guided drug shows encouraging activity in metastatic breast cancer
Date:12/12/2009

SAN ANTONIO, TXA new antibody-drug compound shrank or halted the growth of metastatic breast tumors in almost half of a group of patients whose HER2-positive cancer had become resistant to standard therapies, according to early data from a multicenter Phase 2 clinical trial led by a Dana-Farber Cancer Institute researcher.

The findings will be presented at the 32nd annual CTRC-AACR San Antonio Breast Cancer Symposium on Saturday, Dec. 12 (Abstract 710, Henry B. Gonzalez Convention Center, Exhibit Hall B, 7-9 a.m. CT).

Ian Krop, MD, PhD, principal investigator of the study, will report that the hybrid agent, called T-DM1, shrank tumors by 30 percent or more in 40 percent of women with confirmed HER2-positive cancers. Another 13 percent had stable disease for at least six months, for a total clinical benefit rate of approximately 53 percent. The median time before the disease progressed was 7.3 months, including both responders and non-responders. Patients received T-DM1 as long as it was effective and well-tolerated. A total of 110 women were enrolled in the study.

T-DM1 is comprised of the cell-killing drug DM1 and is chemically linked to the monoclonal antibody trastuzumab, which selectively binds to the HER2 growth signal receptor, which is highly overexpressed in HER2-positive breast tumors. Approximately 20 percent of breast cancers are HER2-postive.

Trastuzumab, developed by Genentech and sold under the name Herceptin, has markedly improved the treatment of HER2-positive cancer, but resistance to trastuzumab is a significant problem.

"The antibody binds to the HER2 protein on tumor cells and delivers the drug (DM1) selectively to them but not to normal cells," Krop explained. "This allows us to deliver high doses of the chemotherapy directly to tumor cells. And at the same time, the antibody continues to block the HER2 growth signals."

Krop said that one of the unique features of the study is that it is the first to address a population of women with metastatic HER2-positive breast cancer whose disease had progressed despite treatment with all of the FDA-approved drugs for this disease (trastuzumab, lapatinib and several chemotherapy agents).

On average, the women had metastatic breast cancer for three years and previously received seven different drugs for their cancer.

Although patients experienced side effects that included nausea, fatigue and lowered platelet counts, these effects were typically mild and the drug in general was well-tolerated, said Krop.

In addition to the current study, T-DM1 is being tested in larger Phase 3 trials comparing its effectiveness with that of other combined therapies.


'/>"/>

Contact: Bill Schaller
william_schaller@dfci.harvard.edu
617-632-4090
Dana-Farber Cancer Institute
Source:Eurekalert

Related medicine news :

1. New study shows promise in reducing surgical risks associated with surgical bleeding
2. New research shows how chronic stress worsens neurodegenerative disease course
3. Embryonic Human Stem Cells May Help Repair Heart Muscle, Lab Study Shows
4. Circulating fats kill transplanted pancreas cells, study shows
5. New Heart Pump Shows Promise in Trial
6. Novel 3-D cell culture model shows selective tumour uptake of nanoparticles
7. New Survey Shows Americans are Still Concerned About Food Safety, Yet Still Not Smart About What They Like to Eat
8. Australian-led international study shows blood pressure drugs cut death rate in type 2 diabetes
9. Amid Improving Life Expectancy Rates, Risk of Premature Death is Still Significant for Americans, New Study Shows
10. Avocados may help prevent oral cancer, OSU study shows
11. New Poll Shows Public Distrusts Flawed Healthcare Approach Favored by Governor and Speaker in AB 8
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... San Fernando Valley, CA (PRWEB) , ... December 07, 2016 , ... ... Sculptra can be used in several ways to restore a more youthful appearance to ... doctors , now offer Sculptra, along with a variety of other treatments, to rejuvenate ...
(Date:12/7/2016)... ... December 07, 2016 , ... ODU, a ... the US market its advanced highly customizable contact technology solutions. , ODU Single ... advanced technologies are ideal for a wide range of applications that require customization ...
(Date:12/7/2016)... ... ... AlignLife clinics nationwide are giving back to their communities by collecting toys during ... wrapped tightly under a Christmas Tree. AlignLife hopes to spread the joy and ... exchange for generous donations, customers will receive a gift in return. Anyone who ...
(Date:12/7/2016)... ... December 07, 2016 , ... Facial plastic surgeon, Dr. ... season by donating a portion of proceeds to two local organizations: North Chicago Animal ... Control & Friends is a team of authorized and trained volunteers who support ...
(Date:12/7/2016)... California (PRWEB) , ... December 07, 2016 , ... "ProBrand ... any and all media," said Christina Austin - CEO of Pixel Film Studios. , ... with easy to use drop zones. Editors can select from a variety of flip ...
Breaking Medicine News(10 mins):
(Date:12/6/2016)...  Alopexx Oncology, LLC announced data from a Phase ... (immunocytokine) composed of interleukin-2 and a CD20-targeting monoclonal antibody. ... cells as Rituxan and maintains the activities of both ... in tumor targeting, engagement of the immune system, and ... the study (abstract #95954) were presented at the 58 ...
(Date:12/6/2016)... -- Diabetes & Obesity Drug Development Pipeline Review, 2016 ... is currently dominated by therapeutics indicated for type 1 ... and the majority of the pipeline, in terms of ... these indications. While products indicated for obesity do not ... large number of these products in the pipeline, with ...
(Date:12/6/2016)... The pen needles market is projected to reach USD ... 2016, growing at a CAGR of 11.2% during the ... years, the pen needles market has witnessed various technological ... for safety injections in the healthcare industry. These advancements ... with an aim to reduce pain, increase comfort, and ...
Breaking Medicine Technology: